Lexaria receives five new patents, including two for diabetes treatment

Lexaria Bioscience (LEXX) provided an update on additional new intellectual property granted to the Company as a result of its ongoing research and development programs. This new IP is recognized with the awarding of 5 new patents. In Lexaria’s patent Family #21, Compositions and Methods for Treating Hypertension, the company received 2 new patents in Japan, both issued on February 20, 2026 with a term ending on April 25, 2043. Prior to this, Lexaria already had 3 US and 1 European granted patents in this same family. In patent Family #24, Compositions and Methods for Treating Epilepsy, the company have received 1 new Australian patent issued on February 12, 2026 with a term ending on February 20, 2044. Prior to this, Lexaria already had 6 US; 1 European Union; and 4 previous Australian patents in this patent Family #24. Finally, in patent Family #27, Compositions and Methods for Treating Diabetes, the company received 2 new Australian patents issued on February 12, 2026 with a term ending on December 3, 2044. Prior to this, Lexaria had 2 granted US patents in this newest of patent families.